Published Manuscripts (2018)

Dempsey M, Mocarski M, Langer J, Hunt B. IDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine U100 plus insulin aspart in the U.S. Endocrine Practice 2018; 24(9): 796-804.

Dempsey M, Mocarski M, Langer J, Hunt B. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 2018; 21(11): 1110-8.

Drummond R, Malkin S, Du Preez M, Lee XY, Hunt B. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 2018; 20(10): 2371-8.

Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism 2018; 20(8): 1921-7.

Gyldmark M, Lampe K, Ruof J, Pöhlmann J, Hebborn A, Kristensen FR. Is the EUnetHTA HTA Core Model^® fit for purpose? Evaluation from an industry perspective. International Journal of Technology Assessment in Health Care 2018; 34(5): 458-63.

Pollock RF, Muduma G. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy 2018; 35(12): 2128-37.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health 2018; 21(6): 724-31.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén, Hansen LL, Tutkunkardas D, Buse JB, On behalf of the DEVOTE Study Group. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy 2018; 9(3): 1217-32.

Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy 2018; 9(3): 951-61.

Wang L, Ye Q, Nielsen OK, Gadegaard A, Valentine WJ, Hunt B, Wang L. Evaluation of the Long-Term Impact of Improving Care for People with Type 2 Diabetes in China. Value in Health Regional Issues 2018; 15: 169-74.

Pollock RF, Chubb B, Valentine WJ, Heller S. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes, Metabolic Syndrome and Obesity 2018; 11: 217-26.

Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Applied Health Economics and Health Policy 2018; 16(3): 357-66.

Pollock RF, Meckley LM. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. ClinicoEconomics and Outcomes Research 2018; 10: 223-9.

Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics 2018; 21(2): 144-51.

Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy 2018; 9(1): 87-99.